Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.05 -0.44 (-1.21%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗

July 14, 2023

Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)

Via Benzinga

Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

July 11, 2023

Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences's Return on Invested Capital Insights ↗

June 29, 2023

Via Benzinga

Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗

June 29, 2023

Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market...

Via Benzinga

Analyst Expectations for Roivant Sciences's Future ↗

June 29, 2023

Via Benzinga

Why Shares of Roivant Sciences Rose Wednesday ↗

June 28, 2023

The pharmaceutical company released fourth-quarter earnings.

Via The Motley Fool

UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 28, 2023

From Roivant Sciences

Via GlobeNewswire

Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness' ↗

June 28, 2023

Via Benzinga

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 28, 2023

From Roivant Sciences

Via GlobeNewswire

Why Roivant Sciences Stock is Trading Higher Today ↗

June 22, 2023

Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with

Via Benzinga

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout ↗

June 22, 2023

The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis.

Via Investor's Business Daily

5 Analysts Have This to Say About Roivant Sciences ↗

June 08, 2023

Via Benzinga

Why Shares of Roivant Sciences Jumped This Week ↗

April 20, 2023

The company's stock benefited from another company's buyout.

Via The Motley Fool

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

June 26, 2023

From Roivant Sciences

Via GlobeNewswire

Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 22, 2023

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private...

Via Benzinga

Why Roivant Sciences Stock Is Perking Up Today ↗

June 22, 2023

Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.

Via The Motley Fool

Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday ↗

June 22, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

June 22, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

June 21, 2023

From Roivant Sciences

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 ↗

June 08, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission ↗

May 16, 2023

Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old...

Via Benzinga

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

May 16, 2023

From Roivant Sciences

Via GlobeNewswire

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? ↗

April 23, 2023

Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.

Via The Motley Fool

These 2 Growth Stocks Might Be Incredibly Undervalued Right Now ↗

April 20, 2023

These two biopharma stocks could be poised for a major growth spurt.

Via The Motley Fool

EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis ↗

April 17, 2023

While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up.

Via Benzinga

These 3 Nasdaq Stocks Are on Fire Today: Here's Why ↗

April 17, 2023

A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.

Via The Motley Fool

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom ↗

April 17, 2023

Merck is branching into immune-mediated diseases with this takeover.

Via Investor's Business Daily

Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

April 17, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...

Via Benzinga

Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory

April 04, 2023

From Lokavant

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.